Medicare Expenditures of Atezolizumab for a Withdrawn Accelerated Approved Indication.
cross_sectional · Level IV
Where this comes from
- Record sourced from PubMed, PMID 34554196.
- Also identified by DOI 10.1001/jamaoncol.2021.4757 and PMC identifier 8461543.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This cross-sectional study examines atezolizumab as a second-line treatment for malignant urothelial carcinoma, which received accelerated US Food and Drug Administration approval, although the manufacturer’s confirmatory trial did not identify benefits.
Medical subject headings
- Health Expenditures
- Medicare